VX-765

CAT: 0421-27779-1Size: 100 mgDry Ice: NoHazardous: No
CAT#:0421-27779-1Size:100 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Background
VX-765 is an orally-absorbed pro-drug of VRT-043198, a potent and selective inhibitor of ICE/caspase-1 sub-family caspases. VRT-043198 exhibits 100-10,000-fold selectivity against other caspase-3 and -6-9. In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT-043198 inhibited the release of Interleukin (IL) -1beta and IL-18, but had little effect on the release of several other cytokines, including IL-1alpha, tumor necrosis factor-alpha, IL-6 and IL-8. VX-765 has been shown to inhibit acute seizures in preclinical models of acute epilepsy and has shown activity in preclinical models of chronic epilepsy that do not respond to standard anti-epileptic drugs.
Description
VX-765, also known as Belnacasan, is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy.
CAS Number
273404-37-8
Purity
≥ 96%
Solubility
Insoluble in H2O; ≥ 313 mg/mL in DMSO; ≥ 50.5 mg/mL in EtOH with ultrasonic
Molecular Formula
C24H33ClN4O6
Shipping Conditions
Room Temperature (continental US) or Gel Packs
Storage Conditions
Store desiccated at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Calculated Molecular Weight
508.99 Da

Related Products

CatalogName
27053VX-222
27051Telaprevir (VX-950)

Alternative Products

CatalogName
7143/50VX 765
2781-25VX-765
MBS386389-01VX-765 (Belnacasan)
A10984-100VX-765 100mg
TRC-V900605-75MGVX-765 Hemiketal
A10984-5VX-765 5mg
C08374-01Belnacasan (VX-765)
A10984-10VX-765 10mg
A10984-50VX-765 50mg

Popular Products